DETERMINE TIME TO DEVELOPMENT OF AIDS DEFINING COMPLICATIONS & INFECTIONS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。初步确定父母研究ACTG 362受试者中艾滋病定义并发症和严重细菌感染的总体比率和风险因素。在研究队列中确定心血管疾病的总体发生率和危险因素(如甘油三酯、胆固醇、腰臀比)。值得关注的心血管事件包括：心肌梗死、冠状动脉血运重建手术、心绞痛、心脏性猝死和中风。2.比较被分配接受阿奇霉素治疗的受试者和被分配接受安慰剂治疗的受试者出现艾滋病相关并发症和严重感染或心血管疾病的时间。3.评估基线和随访期间的CD4计数和HIV RNA水平之间的关系，以及机会性感染和其他艾滋病毒相关并发症的风险。4.比较被分配接受阿奇霉素治疗的受试者和接受安慰剂治疗的受试者的死亡率。5.确定在接受高效抗逆转录病毒疗法(HAART)期间免疫严重抑制并恢复CD4计数的患者队列中认知恶化的风险。6.确定与认知能力下降有关的免疫学(CD4计数)和病毒学(血浆HIV RNA水平)标记物和特定药物(特别是PI)。7.评估与长期坚持服用抗逆转录病毒药物有关的因素，以及长期坚持对病毒抑制的影响以及对机会性和严重细菌感染和心血管疾病的发展的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Determine the overall rates of and risk factors for AIDS-defining complications and serious bacterial infections in subjects in the parent study, ACTG 362. Secondary 1. Determine the overall rates and risk factors (e.g. triglycerides, cholesterol, waist-to-hip ratio) for the development of cardiovascular disease in the study cohort. Cardiovascular events of interest include: myocardial infarction, coronary artery revascularization procedures, angina, sudden cardiac death, and stroke. 2. Compare the time to development of AIDS-defining complications and serious infections or cardiovascular disease in subjects who were assigned to receive Azithromycin to those who were assigned to receive placebo. 3. Evaluate the association between CD4 counts and HIV RNA levels at baseline and during follow-up and risk of opportunistic infections and other HIV-related complications. 4. Compare mortality in subjects who were assigned to receive Azithromycin to those who were assigned to receive placebo. 5. Define the risk of cognitive deterioration in a cohort of patients who have been severely immunosuppressed and recovered CD4 counts while taking Highly Active Antiretroviral Therapy (HAART). 6. Identify immunologic (CD4 counts) and virologic (plasma HIV RNA levels) markers and specific drugs (especially PIs) associated with cognitive decline. 7. Evaluate factors associated with long-term adherence to antiretroviral medications and the effect of adherence on viral suppression over time and on the development of opportunistic and serious bacterial infections and cardiovascular disease.